Get to know our clinical trials

Clinical trial comparing teclistamab in combination with daratumumab S.C. versus daratumumumab S.C., pomalidomide and dexamethasone or daratumumumab S.C., bortezomib and dexamethasone in patients with refractory or relapsed multiple myeloma.

THE OBJECTIVE OF THIS STUDY IS TO DETERMINE THE DIFFERENCE BETWEEN TECLISTAMAB IN COMBINATION WITH DARATUMUMAB (TEC-DARA) AND DARATUMUMAB, POMALIDOMIDE AND DEXAMETHASONE (DPD) OR DARATUMUMAB, BORTEZOMIB (VELCADE) AND DEXAMETHASONE (DVD) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE NOT RESPONDED TO THE MOST RECENT TREATMENT.

Status
In recruitment
headquarters
Pamplona

Technical Summary

  • RANDOMIZED PHASE 3 STUDY COMPARING TECLISTAMAB IN COMBINATION WITH DARATUMUMAB S.C. (TEC-DARA) VERSUS DARATUMUMAB S.C., POMALIDOMIDE AND DEXAMETHASONE (DPD) OR DARATUMUMAB S.C., BORTEZOMIB AND DEXAMETHASONE (DVD) IN PATIENTS WITH REFRACTORY OR RELAPSED MULTIPLE MYELOMA (MAJESTEC-3). IMMUNOTHERAPY.
  • Code EudraCT: 2020-004742-11
  • Protocol number: 64007957MMY3001
  • Promoter: Janssen-Cilag
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.